

US Pharmacopeia

FREDERICK LIFE SCIENCE PRODUCTION FACILITY

7135 ENGLISH MUFFIN WAY, FREDERICK, MARYLAND



NGLE-TENANT MISSION CRITICAL LIFE SCIENCE INVESTMENT OPPORTUNITY





Executive Summary

Address	7135 English Muffin Way, Frederick, MD 21704
Built	2009 / 2016
Rentable Area	63,054 RSF
Tenancy	100% leased to US Pharmacopeia
Lease Structure	Triple Net
Annual Escalations	3.0%
Termination/Contraction Options	None
Lease Expiration	June 2031
Use	Mission critical, life science production facility
Parking	125 Spaces (2.0/1,000 RSF)



100% Leased to US Pharmacopeia Through June 2031 → No Termination nor Contraction Options

- USP has been the sole occupant of the Property since initial construction, and in 2015 executed an expansion that more than doubled their premise and resulted in the construction of a new wing to the Property on a build-to-suit basis
- The Property is 100% leased to US Pharmacopeia through June 2031 with no termination nor contraction options
- The lease has attractive 3% annual escalations
- Property will be delivered free and clear of debt



INVESTMENT HIGHLIGHTS



100% leased

to US Pharmacopeia ("USP") through June 2031 with no termination nor contraction options



NNN

lease with 3% annual escalations



USP

is a well-capitalized nonprofit whose role in the global pharmaceutical industry is mandated by federal law

Mission critical

& highly specialized life science facility that serves as tenant's primary production facility globally Strategically located in

Frederick, MD

a vibrant life science cluster with 0.4% total availability

In close proximity to

Fort Detrick

which houses some of the US government's most advanced biological research functions: National Interagency Biodefense Campus, National Biodefense Analysis and Countermeasures Center, the US Army Medical Research Institute of Infectious Diseases and the US Army Medical Research and Material Command Center, amongst many others



The National Cancer Institute,
AstraZeneca, ThermoFisher
Scientific, Charles River
Laboratories, Lonza, and
Qiagen all maintain a
significant presence in the
Frederick market







US Pharmacopeia is a Well-Capitalized Non-Profit with a Central Role in the Global Pharmaceutical Industry that is Mandated by Federal Law

- USP is a non-profit scientific organization with a central role in the global pharmaceutical industry that is mandated by federal law under the Food, Drug, & Cosmetic Act (FDCA)
- USP helps to both establish the standards for pharmaceutical quality and purity and produces the reference standards against which many pharmaceutical products are tested
- USP standards are recognized in over 140 countries globally, and the organization has 14 locations around the world
- USP carries over \$80 MM of cash and short-term investments on its balance sheet
- USP has averaged \$325 MM in revenue over the last 3 years and has a highly profitable business model

Highly Specialized, Mission Critical Life Science Facility Serving as US Pharmacopeia's Primary Production Facility Globally

- The Property features high grade clean rooms and lab facilities for production of reference standards and freezer and cold storage facilities for warehousing, and also serves as USP's global distribution facility
- The Property is USP's primary production facility globally and serves a mission critical role not only for USP but for the entire global pharmaceutical industry





Strategically Located in Frederick, Maryland, a Vibrant Life Science Cluster with 0.4% Total Availability

- The Property is strategically located in Frederick, Maryland outside the Washington, DC blast zone but still in close proximity to USP's global headquarters in Rockville, Maryland
- Frederick is a rapidly growing 2.2 MSF private sector life science market anchored by the federal government and top bio-pharma private sector tenants
- Since the early 1940's Frederick's Fort Detrick has been a bastion of the US Government's biological warfare and bio-defense programs and Frederick is home to many of the Government's most critical biotech functions
- The Frederick National Laboratories is the single largest NIH contract recipient in the United States annually and has 4 distinct facilities in Frederick
- Notable private sector tenancy in Frederick includes AstraZeneca, ThermoFisher Scientific, Lonza, Charles River, and Qiagen, all of which have mission critical Frederick facilities
- The Frederick cluster currently has a total availability rate of 0.4% with only 3,285
 RSF of direct vacancy







Frederick is Home To the US Government's Most Advanced Biological Research Programs







FORT DETRICK

Since the 1940s, Fort Detrick has been the US military's primary biological warfare and bio-defense research center. Today, it is home to the following agencies:

- US Army Medical Research Institute of Infectious Disease (USAMRIID)
- US Army Medical Research and Material Command (USAMRMC)
- National Interagency Biodefense Campus (NIBC)
- National Biodefense Analysis and Countermeasures Center (NBACC)
- National Institute of Allergies and Infectious Diseases (NIAID)
- Centers for Disease Control and Prevention (CDC)
- National Cancer Institute

FREDERICK NATIONAL LABORATORIES

The Frederick National Laboratories – run by Leidos Biomedical Services on behalf of the National Institutes of Health – is the single largest NIH contract recipient annually and since 2010 has secured \$7.7 billion in contracts (3.5x the next largest recipient). The Frederick National Laboratory maintains 4 facilities in Frederick:

- Advanced Technology Research Facility (ATRF) 8560 Progress Drive, Frederick, MD
- Clinical Monitoring Research Program (CMRP) 5705 Industry Lane, Frederick, MD
- Frederick National Laboratory Campus 1050 Boyles Street, Frederick, MD
- Pilot Plant 7116 Geoffrey Way, Frederick, MD



INVESTMENT ADVISORY

James A. Meisel

Senior Managing Director (o) 202.533.2505 (c) 301.922.6110 Jim.Meisel@am.jll.com

David B. Baker IV

Director (o) 202.777.2301 (c) 410.804.6518 D.Baker@am.jll.com

Matthew T. Nicholson

Managing Director (o) 202.533.2502 (c) 410.353.3041 Matt.Nicholson@am.jll.com

Andrew M. Weir

Senior Managing Director (o) 202.533.2504 (c) 202.286.0477 Andrew.Weir@am.jll.com

DEBT SPECIALIST

Daniel McIntyre

Senior Director (o) 202.533.2506 Daniel.McIntyre@am.jll.com



Jones Lang LaSalle Americas, Inc. ("ILL") has been engaged by the sponsor ("Sponsor") of the property to arrange the placement of equity. Information concerning the property and Sponsor described herein has been obtained from sources other than JLL, and neither Sponsor nor JLL, nor their respective equity holders, officers, employees and agents makes any representations or warranties, express or implied, as to the accuracy or completeness of such information. Any opinions, assumptions, or estimates contained herein are projections only and used for illustrative purposes and may be based on assumptions or due diligence criteria different from that used by a purchaser, and JLL, its officers, directors, employees and agents disclaim any liability that may arise from, be based upon or relate to the use of the information contained herein. Prospective purchasers should conduct their own independent investigation and rely on those results. The information contained herein is subject to change without notice. ©2020. Jones Lang LaSalle IP, Inc. All rights reserved.

**The outbreak of the COVID-19 virus (novel coronavirus) since the end of January 2020 has resulted in market uncertainty and volatility. While the economic impact of a contagion disease generally arises from the uncertainty and loss of consumer confidence, its impact on real estate values is unknown at this stage. Given the prevailing domestic and global uncertainty arising from the Coronavirus, we recommend that the intended recipients of this information regularly seek our guidance.

